<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596722</url>
  </required_header>
  <id_info>
    <org_study_id>POM01</org_study_id>
    <nct_id>NCT04596722</nct_id>
  </id_info>
  <brief_title>Oral Pomegranate Extract on the Microbiome and Skin Biophysical Properties</brief_title>
  <official_title>Prospective Randomized Double-Blind Placebo Controlled Study of Oral Pomella on the Microbiome and Skin Biophysical Properties</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Integrative Skin Science and Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Verdure Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Integrative Skin Science and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pomegranate extract (Pomella) is well known for its antioxidant properties due to its&#xD;
      phenolic compounds. It has also been shown to increase the amount of short chain fatty acid&#xD;
      producing Lactobacillus and Bifidobacteria genera. Short chain fatty acids are thought to&#xD;
      have an anti-inflammatory effect on the sebaceous glands. Previous studies have concluded&#xD;
      that pomegranate extract may act as a prebiotic in the body and subsequently increasing the&#xD;
      gastrointestinal microbial diversity and by producing short chain fatty acids that may have&#xD;
      systemic beneficial effects especially on the skin.&#xD;
&#xD;
      Therefore, the aim of this study is to assess how Pomella alters the gut microbiome and the&#xD;
      blood level of short chain fatty acids in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Actual">March 24, 2021</completion_date>
  <primary_completion_date type="Actual">March 24, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Shift in Gut Microbiome Diversity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Stool is collected and analyzed for species of bacteria through nucleic acid sequencing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gut Microbiome Changes- Abundance and Presence of Short Chain Fatty Acid producing Bacteria</measure>
    <time_frame>4 weeks</time_frame>
    <description>Stool is collected and analyzed for species of bacteria through nucleic acid sequencing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment for GI Distress</measure>
    <time_frame>4 weeks</time_frame>
    <description>Subjective GI based Questionnaire that will assess for distress (one combined metric that accounts for stooling, gas, and discomfort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Skin Brightness - Device based</measure>
    <time_frame>4 weeks</time_frame>
    <description>SkinColorCatch colorimeter RGB range: 25-246 per channel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sebum Excretion Rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>Delfin Sebumeter: 0-150 micrograms/cm^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Transepidermal Water Loss</measure>
    <time_frame>4 weeks</time_frame>
    <description>Delfin Vapometer 0-300g/m^2h; Delfin MoisturemeterSC 0-150</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Appearance of Facial Redness and Facial Skin Tone</measure>
    <time_frame>4 weeks</time_frame>
    <description>SkinColorCatch colorimeter RGB range: 25-246 per channel; BTBP Clarity Mini 3D_V5 camera</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shift in the Blood Short Chain Fatty Acid Levels</measure>
    <time_frame>4 weeks</time_frame>
    <description>Short chain fatty acids are measured from a venipuncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skin brightness - image based</measure>
    <time_frame>4 weeks</time_frame>
    <description>BTBP Clarity Mini 3D Camera</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Skin Microbiome Diversity</measure>
    <time_frame>4 weeks</time_frame>
    <description>The alpha and beta diversity of facial skin microbiome collections will be evaluated</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Human Microbiome</condition>
  <arm_group>
    <arm_group_label>Assigned Interventions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral active pomella taken by mouth once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral placebo taken by mouth once per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pomella</intervention_name>
    <description>Pomella® Pomegranate Whole Fruit Extract containing 75 mg punicalagin in white/white HPMC size &quot;1&quot; capsules packed in white color HDPE bottle of 30 counts</description>
    <arm_group_label>Assigned Interventions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>White/white HPMC size &quot;1&quot; capsules each containing 97.67% Maltodextrin, 0.10% Tartrazine color, 0.22% Brown Color, 2.01% Aerosil packed in white color HDPE bottle of 30 counts</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects aged 25-55&#xD;
&#xD;
          2. Must be willing to comply with all protocol requirements&#xD;
&#xD;
          3. Must be willing to have flash photo facial images taken with the imaging systems&#xD;
&#xD;
          4. Males must be willing to shave any facial hair&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any systemic or antibiotics (injected or oral) within 6 months of starting study&#xD;
&#xD;
          2. Any topical antibiotic or benzoyl peroxide within 1 month of starting study or any&#xD;
             subject unwilling to refrain from washout of topical antibacterial or benzoyl peroxide&#xD;
             ingredient.&#xD;
&#xD;
          3. No intake of alcohol or tea throughout the duration of the study.&#xD;
&#xD;
          4. No more than 1 8 oz cup of coffee per week throughout the duration of the study.&#xD;
&#xD;
          5. No more than 1 cup of berries (strawberries, blueberries, raspberries, blackberries,&#xD;
             etc.) per week throughout the duration of the study.&#xD;
&#xD;
          6. No intake of pomegranate, or pomegranate-containing drinks throughout the duration of&#xD;
             the study.&#xD;
&#xD;
          7. No intake of chocolate (in any form) throughout the duration of the study.&#xD;
&#xD;
          8. No more than 1 cup of fermented dairy products per week throughout the duration of the&#xD;
             study.&#xD;
&#xD;
          9. Any oral probiotic or prebiotic supplementation within past 1 month&#xD;
&#xD;
         10. Subjects must have no history of malignancy or cancer or diagnosis of gastrointestinal&#xD;
             inflammatory diseases, no history or diagnosis of epilepsy, no history or diagnosis of&#xD;
             immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus,&#xD;
             rheumatoid arthritis)&#xD;
&#xD;
         11. Has a condition or is on medication the investigator and/or designee believe could&#xD;
             jeopardize the safety of the subject, interfere with the evaluation, or confound the&#xD;
             interpretation of the study results&#xD;
&#xD;
         12. Women who have been pregnant in the last three months, are pregnant, preparing to be&#xD;
             pregnant or lactating.&#xD;
&#xD;
         13. Is participating in a concurrent clinical research study or has participated in an&#xD;
             acne or other facial study at this or any other facility in the past 4 weeks&#xD;
&#xD;
         14. Those with BMI higher than 35 kg/m²&#xD;
&#xD;
         15. Commencement of a new diet (such as the ketogenic diet) or supplements within the 1&#xD;
             month prior to initiating participation, at the discretion of the investigator.&#xD;
&#xD;
         16. Use of medications that alter blood lipids, such as statins and anti-hyperlipidemic&#xD;
             medications&#xD;
&#xD;
         17. Is participating in or has participated in a facial study at this or any other&#xD;
             facility in the past 4 weeks. Participation in survey-based studies are approved at&#xD;
             the discretion of the investigator.&#xD;
&#xD;
         18. Has a skin disease on face that will interfere with image collection and assessment in&#xD;
             the opinion of the investigator&#xD;
&#xD;
         19. Refusal to shave or remove facial hair that may interfere with image collection and&#xD;
             assessment.&#xD;
&#xD;
         20. Persons unwilling to avoid the following during the 4 weeks prior and during the&#xD;
             duration of the study: self-tanning, spa tanning, sun tanning, or artificial tanning.&#xD;
&#xD;
         21. Planned vacation to sunny destination with the intention of sun tanning during the&#xD;
             duration of the study.&#xD;
&#xD;
         22. Persons who regularly undergo sauna treatments (dry or wet) or who swim daily.&#xD;
&#xD;
         23. Known allergy or irritation to the supplement or facial products utilized in the study&#xD;
&#xD;
         24. Current tobacco smokers, OR those that have smoked tobacco over the past year, OR a 5&#xD;
             year-pack year history of smoking tobacco&#xD;
&#xD;
         25. Prisoners&#xD;
&#xD;
         26. Adults unable to consent&#xD;
&#xD;
         27. Vegans&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Integrative Skin Science and Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gut microbiome</keyword>
  <keyword>polyphenols</keyword>
  <keyword>skin</keyword>
  <keyword>dermatology</keyword>
  <keyword>pomegranate extract</keyword>
  <keyword>punicalagins</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

